Barbara Lopez Kunz
Chief Executive Officer
As CEO of Caidya, Barbara Lopez Kunz brings more than 30 years of global leadership experience spanning life sciences, clinical research, diagnostics, and public health. Known for her strategic foresight and people-centered leadership, she has served on Caidya’s board since 2022, playing a key role in shaping corporate governance and long-term strategy.
Before joining Caidya, Barbara was President and CEO of the Drug Information Association (DIA), where she led a digital and organizational transformation that deepened global regulatory engagement. At Battelle, she oversaw a multibillion dollar global health and life sciences portfolio, accelerating growth across public health, clinical research, and medical devices. Earlier in her career, she held executive roles at Thermo Fisher Scientific, where she advanced the biosciences division through targeted M&A, and at DuPont, where she served as General Manager. She began her career at ICI in as research scientist before quickly transitioning into broader global leadership positions.
Barbara currently serves on the boards of Werfen and Aptevo Therapeutics (NASDAQ: APVO). She is also vice chair of the board at Children’s National Hospital.
She holds a Master of Science in Polymer Science from the University of Akron and graduated from International Executive Program at INSEAD. She is a DIA Fellow and holds a corporate governance certification from the National Association of Corporate Directors.
